The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio… - leukemia, 2022 - nature.com
The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers …

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

G Garcia‐Manero - American journal of hematology, 2023 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

DA Arber, A Orazi, RP Hasserjian… - Blood, The Journal …, 2022 - ashpublications.org
The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Current challenges and unmet medical needs in myelodysplastic syndromes

U Platzbecker, AS Kubasch, C Homer-Bouthiette… - Leukemia, 2021 - nature.com
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆

P Fenaux, D Haase, V Santini, GF Sanz… - Annals of …, 2021 - annalsofoncology.org
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

G Garcia‐Manero, KS Chien… - American journal of …, 2020 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes

LE Aguirre, N Al Ali, DA Sallman, S Ball, AG Jain… - Leukemia, 2023 - nature.com
Abstract The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk
stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS …

The International Consensus Classification of myelodysplastic syndromes and related entities

RP Hasserjian, A Orazi, A Orfao, M Rozman, SA Wang - Virchows Archiv, 2023 - Springer
Abstract The International Consensus Classification (ICC) of myeloid neoplasms and acute
leukemia has updated the classification of myelodysplastic syndromes (MDSs) and placed …

The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)

F Nguyen-Khac, A Bidet, A Daudignon… - Leukemia, 2022 - nature.com
Karyotype complexity has major prognostic value in many malignancies. There is no
consensus on the definition of a complex karyotype, and the prognostic impact of karyotype …

[HTML][HTML] Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation …

Z DeFilipp, SO Ciurea, C Cutler, M Robin… - … and Cellular Therapy, 2023 - Elsevier
The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic
cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated …